Maribavir Food-Effect Study in Healthy Adults Participants

Study Overview
=================
Brief Summary
-----------------
The main goals of this study are: 1) To assess the relative bioavailability of a single oral dose of 400 mg maribavir commercial (marketed) tablet formulation administered with a low-fat/low-calorie meal relative to administration under fasting conditions. 2) To assess the relative bioavailability of a single oral dose of 400 mg maribavir commercial (marketed) tablet formulation administered with a high-fat/high calorie meal relative to administration under fasting conditions. A single dose of 400 mg maribavir (commercial [marketed] tablet formulation) will be administered orally under 3 different feeding conditions: Fasting (Treatment A), Fed following a low-fat/low-calorie meal (Treatment B), and Fed following a high fat/high-calorie meal (Treatment C). There will be a washout period of a minimum of 72 hours between each single dose of investigational drug (ID) administration on Day 1 in each treatment cycle of 3 days. Pharmacokinetic samples will be collected at pre-dose and up to 36 hours post-dose in each treatment period. Safety and tolerability will be assessed throughout the study by Treatment Emergent Adverse Events (TEAEs), vital signs, electrocardiograms (ECGs), and clinical laboratory evaluations.

Official Title
-----------------
A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Effect of Food on Maribavir (TAK-620) Pharmacokinetics in Healthy Adult Participants

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: Maribavir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Participants must fulfill the following inclusion criteria before the first dose of the Investigational drug (ID) to be eligible for participation in the study: An understanding, ability, and willingness to fully comply with study procedures and restrictions and ability to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent Age 19-55 years, inclusive at the time of consent, at the screening visit. Male, or non-pregnant, non-breastfeeding female who agrees to comply with any applicable contraceptive requirements of the protocol or female of non-childbearing potential. Healthy as determined by the Investigator or designee on the basis of screening evaluations and medical history. Hemoglobin for males greater than or equal to (>=) 135.0 gram per liter (g/L) and females >=120.0 g/L at the screening visit and on Day 1 of Treatment Period 1. Body mass index (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m^2), inclusive with a body weight greater than (>) 50 kilogram (kg) (110 pound [lbs]), at the screening visit. Ability to swallow a dose of the ID. Exclusion Criteria Participants must not be enrolled in the study if they meet any of the following criteria before the first dose of the ID: History or presence of gastritis, Gastrointestinal (GI) tract, hepatic disorder or cholecystectomy, history of treated or untreated Helicobacter pylori, ulcer disease or other clinical GI condition and history of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gall bladder removal, or current recurrent disease that could affect the action, absorption, or disposition of the ID, or clinical or laboratory assessments. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the ID or procedures. Known or suspected intolerance or hypersensitivity to the ID, closely related compounds, or any of the stated ingredients and excipients. Significant illness, as judged by the Investigator or designee, within 2 weeks of the first dose of the ID. Has diarrhea within 4 hours of the first dose of the ID. Donors of blood or blood products (e.g., plasma or platelets) within 60 days prior to receiving the first dose of the ID. Within 30 days prior to the first dose of the ID: Have used any investigational product (if elimination half-life is less than [<] 6 days, otherwise 5 half-lives). Have been enrolled in a clinical study (including vaccine studies) that may impact this study. Have had any substantial changes in eating habits. Systolic blood pressure >140 millimeters of mercury (mmHg) or <90 mmHg, and diastolic blood pressure >90 mmHg or <50 mmHg, at the screening visit. Twelve-lead ECG with corrected QT interval (QTc) >450 millisecond (msec) at the screening visit. Known history of alcohol or other substance abuse within the last year. Male participants who consume more than 21 units of alcohol per week or 3 units per day. Female participants who consume more than 14 units of alcohol per week or 2 units per day. A positive screen for alcohol or drugs of abuse at the screening visit or on Day -1 of Treatment Period 1. A positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody screen at the screening visit. Use of tobacco in any form or other nicotine-containing products in any form. Ex-users must self-report that they have stopped using tobacco for at least 3 months prior to receiving the first dose of the ID. Routine consumption of more than 2 units of caffeine per day or participants who experience caffeine withdrawal headaches. Decaffeinated coffee, tea, or cola are not considered to contain caffeine. Current use of any prescription medication with the exception of hormonal contraceptives and hormonal replacement therapy. Current use of antacids, proton pump inhibitors, or H2 antagonists within 14 days of the first dose of the ID. Inability or unwillingness to consume 100 percent of high-fat meal or low-fat meal (including participants with lactose or gluten intolerance). Recent history (within 1 month) of oral/nasal cavity infections, history of gastroesophageal reflux, asthma treatment with albuterol, or zinc supplementation. Participants with dry mouth syndrome or burning mouth syndrome or participants suffering from dysgeusia.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequence 1: Treatment A + Treatment B + Treatment C<br>Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 under fasting condition as Treatment A, followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 2 administered with a low fat/low calorie meal as Treatment B, and further followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 3 administered with a high fat/high calorie meal as Treatment C. There will be a washout period of minimum of 72 hours between each ID dosing. | Drug: Maribavir<br>* Maribavir 400 mg tablet single oral dose under three different food conditions depending upon the treatment sequence allocation on Day 1 of each treatment period<br>* Other names: TAK-620;|
| Experimental: Sequence 2: Treatment B + Treatment C + Treatment A<br>Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 administered with a low fat/low calorie meal as Treatment B, followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 2 administered with a high fat/high calorie meal as Treatment C, and followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 3 under fasting condition as Treatment A. There will be a washout period of minimum of 72 hours between each ID dosing. | Drug: Maribavir<br>* Maribavir 400 mg tablet single oral dose under three different food conditions depending upon the treatment sequence allocation on Day 1 of each treatment period<br>* Other names: TAK-620;|
| Experimental: Sequence 3: Treatment C + Treatment A + Treatment B<br>Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 administered with a high fat/high calorie meal as Treatment C, followed by maribavir 400 mg tablets, single oral dose on Day 1 of Period 2 under fasting condition as Treatment A, and followed by maribavir 400 mg tablets, single oral dose on Day 1 of Period 3 administered with a low fat/low calorie meal as Treatment B. There will be a washout period of minimum of 72 hours between each ID dosing. | Drug: Maribavir<br>* Maribavir 400 mg tablet single oral dose under three different food conditions depending upon the treatment sequence allocation on Day 1 of each treatment period<br>* Other names: TAK-620;|
| Experimental: Sequence 4: Treatment C + Treatment B + Treatment A<br>Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 administered with a high fat/high calorie meal as Treatment C, followed by maribavir 400 mg tablets, single oral dose on Day 1 of Period 2 administered with a low fat/low calorie meal as Treatment B, and followed by maribavir 400 mg tablets, single oral dose on Day 1 of Period 3 under fasting condition as Treatment A. There will be a washout period of minimum of 72 hours between each ID dosing. | Drug: Maribavir<br>* Maribavir 400 mg tablet single oral dose under three different food conditions depending upon the treatment sequence allocation on Day 1 of each treatment period<br>* Other names: TAK-620;|
| Experimental: Sequence 5: Treatment A + Treatment C + Treatment B<br>Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 under fasting condition as Treatment A, followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 2 administered with a high fat/high calorie meal as Treatment C, and followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 3 administered with a low fat/low calorie meal as Treatment B. There will be a washout period of minimum of 72 hours between each ID dosing. | Drug: Maribavir<br>* Maribavir 400 mg tablet single oral dose under three different food conditions depending upon the treatment sequence allocation on Day 1 of each treatment period<br>* Other names: TAK-620;|
| Experimental: Sequence 6: Treatment B + Treatment A + Treatment C<br>Participants will receive maribavir 400 mg tablet, single oral dose on Day 1 of Period 1 administered with a low fat/low calorie meal as Treatment B, followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 2 under fasting condition as Treatment A, and followed by maribavir 400 mg tablet, single oral dose on Day 1 of Period 3 administered with a high fat/high calorie meal as Treatment C. There will be a washout period of minimum of 72 hours between each ID dosing. | Drug: Maribavir<br>* Maribavir 400 mg tablet single oral dose under three different food conditions depending upon the treatment sequence allocation on Day 1 of each treatment period<br>* Other names: TAK-620;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Observed Plasma Concentration (Cmax) of Maribavir | Cmax of maribavir in plasma will be assessed. | Pre dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36-hours post-dose | 
| Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Maribavir | AUClast of maribavir in plasma will be assessed. | Pre dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36-hours post-dose | 
| Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC 0-infinity) of Maribavir | AUC 0-infinity of maribavir in plasma will be assessed. | Pre dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 36-hours post-dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants who Experienced at Least one TEAE and Serious TEAE (Including Fatal Events) | An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant who has signed informed consent to participate in a study; it does not necessarily have to have a causal relationship with the treatment. TEAEs are defined as AEs with a start date on or after the first dose of the ID, or with a start date before the date of first dose of the ID but increasing in severity after the first dose of the ID. An SAE is any untoward medical occurrence that at any dose results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality or birth defect, an important medical event. | From start of study drug administration up to 7 days after the last dose of maribavir (up to Day 14) | 
| Number of Participants Based on Severity of TEAE | Severity of an TEAE will be determined by following criteria: Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. | From start of study drug administration up to 7 days after the last dose of maribavir (up to Day 14) | 
| Number of Participants Based on Causality of TEAE | Causality of TEAE to the ID will be assessed using the following categories: Related: An AE that follows a reasonable temporal sequence from administration of an ID (including the course after withdrawal of the drug), or for which a causal relationship is at least a reasonable possibility, that is (i.e.), the relationship cannot be ruled out, although factors other than the ID, such as underlying diseases, complications, concomitant drugs and concurrent treatments, may also be responsible; Not Related: An AE that does not follow a reasonable temporal sequence from administration of an ID and/or that can reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments. | From start of ID administration up to 7 days after the last dose of maribavir (up to Day 14) |